Medicamen Biotech DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.81×	0.82×	0.66×	0.73×	0.86×
	1.03×	0.97×	1.45×	0.86×	0.97×
	6.0%	6.3%	4.2%	8.4%	12.4%
	0.59×	0.59×	0.55×	0.63×	0.51×
	1.35×	1.35×	1.40×	1.47×	1.44×
	3.9%	3.9%	3.1%	4.9%	7.7%
	4.0%	4.0%	3.4%	5.6%	7.7%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MEDICAMEQ₹251.90

Medicamen Biotech Limited

· Pharma & Health

₹ CrorePeersMEDICO AAREYDRUGS NECLIFE HALEOSLABS ALBERTDAVD NATCAPSUQ VALIANTLAB BALPHARMAMcap ₹342 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.86	0.73	0.66	0.82	0.81
Interest Burden (Pretax/EBIT) ×	0.97	0.86	1.45	0.97	1.03
EBIT Margin %	12.43	8.45	4.18	6.25	5.97
Asset Turnover ×	0.51	0.63	0.55	0.59	0.59
Financial Leverage (Assets/Equity) ×	1.44	1.47	1.40	1.35	1.35
ROE (5-step product, year-end total equity) %	7.68	4.90	3.09	3.95	3.95
ROE (owners' profit / average owners' equity) %	7.67	5.55	3.44	3.95	3.95

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.